Endo agreed to pay up to $464.9 million to resolve claims around the marketing of its former opioid pain medication Opana ER.
The company this week announced a series of settlements, including a bankruptcy agreement that calls for 10 annual payments to the federal government totaling $364.9 million. The deal also includes an additional payment of up to $100 million, depending on the “business performance of the new company.”
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.